SCHEMBL625321

SCHEMBL625321

COC(=O)c1cc(Br)oc1Br

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.45
HTT P42858 1/20 0.45
HSD17B10 Q99714 3/20 0.42
ALDH1A1 P00352 5/20 0.40
KDM4E B2RXH2 4/20 0.40
CA12 O43570 3/20 0.40
CA1 P00915 3/20 0.40
CA2 P00918 3/20 0.40
CA7 P43166 3/20 0.40
CA9 Q16790 3/20 0.40
CA14 Q9ULX7 3/20 0.40
HPGD P15428 2/20 0.40
PDK2 Q15119 1/20 0.40
PDK4 Q16654 1/20 0.40
NR4A2 P43354 1/20 0.39
LMNA P02545 1/20 0.38
TSHR P16473 1/20 0.38
MAPT P10636 3/20 0.38
GAA P10253 2/20 0.38
GLA P06280 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1598651 0.82 ALDH1A1 (0.46) KMT2AHTTHSD17B10ALDH1A1KDM4E
SCHEMBL10264712 0.81 HTT (0.40) KMT2AHTTHSD17B10ALDH1A1KDM4E
SCHEMBL623140 0.79 MAOB (0.49) KMT2AHSD17B10ALDH1A1KDM4ECA12
SCHEMBL28592709 0.78 KMT2A (0.41) KMT2AHTTHSD17B10ALDH1A1KDM4E
SCHEMBL1674226 0.78 KMT2A (0.41) KMT2AHTTHSD17B10ALDH1A1KDM4E
SCHEMBL24419074 0.78 KMT2A (0.41) KMT2AHTTHSD17B10ALDH1A1KDM4E
SCHEMBL3095786 0.77 KMT2A (0.40) KMT2AHTTHSD17B10ALDH1A1KDM4E
SCHEMBL28593397 0.77 KMT2A (0.40) KMT2AHTTHSD17B10ALDH1A1KDM4E
SCHEMBL16564102 0.75 NPC1 (0.40) KMT2AHTTHSD17B10ALDH1A1KDM4E
SCHEMBL28595161 0.75 HSD17B10 (0.42) KMT2AHTTHSD17B10ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250296936-A1 SARS-COV2 MAIN PROTEASE INHIBITORS GILEAD SCIENCES, INC. 2025-09-25 US disclosed
US-9062038-B2 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2015-06-23 US disclosed
US-9062038-B2 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2015-06-23 US disclosed
US-9062038-B2 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2015-06-23 US disclosed
US-20130267563-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-10-10 US disclosed
US-20130267563-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-10-10 US disclosed
US-20130267563-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-10-10 US disclosed
WO-2012021611-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-02-16 WO disclosed
WO-2012021611-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130267563-A1 HETEROARYLS AND USES THEREOF RICTOR, MTOR, AKT1S1 KMT2A 2381/4885HTT 69/4885HSD17B10 226/4885
US-20250296936-A1 SARS-COV2 MAIN PROTEASE INHIBITORS ACE2, TMPRSS2, ACE KMT2A 3388/4885HTT 3737/4885HSD17B10 372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.